waveLINE-007: Phase 2 study of zilovertamab vedotin (ZV) in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) in previously untreated diffuse large B-cell lymphoma (DLBCL).

被引：0
|
作者：
Lavie, David
Ozcan, Muhit
Paszkiewicz-Kozik, Ewa
Barca, Eva Gonzalez
Kim, Tae Min
Puccini, Benedetta
Wang, Siruo
Yusuf, Rushdia
Marinello, Patricia
Kim, Won Seog
机构：
[1] Hadassah Med Ctr, Jerusalem, Israel
[2] Ankara Univ, Sch Med, Ankara, Turkiye
[3] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland
[4] Univ Barcelona, Inst Catala Oncol Hosp, IDIBELL, Barcelona, Spain
[5] Seoul Natl Univ Hosp, Seoul, South Korea
[6] Unit AOU Careggi, Florence, Italy
[7] Merck & Co Inc, Rahway, NJ USA
[8] Samsung Med Ctr, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7589
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase 2 study of polatuzumab vedotin plus bendamustine plus rituximab in relapsed/refractory diffuse large B-cell lymphoma
    Terui, Yasuhito
    Rai, Shinya
    Izutsu, Koji
    Yamaguchi, Motoko
    Takizawa, Jun
    Kuroda, Junya
    Ishikawa, Takayuki
    Kato, Koji
    Suehiro, Youko
    Fukuhara, Noriko
    Ohmine, Ken
    Goto, Hideki
    Yamamoto, Kazuhito
    Kanemura, Nobuhiro
    Ueda, Yasunori
    Ishizawa, Kenichi
    Kumagai, Kyoya
    Kawasaki, Atsuko
    Saito, Tomohisa
    Hashizume, Misato
    Shibayama, Hirohiko
    CANCER SCIENCE, 2021, 112 (07) : 2845 - 2854
  • [42] A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL)
    Younes, Anas
    Sehn, Laurie H.
    Johnson, Peter
    Zinzani, Pier Luigi
    Hong, Xiaonan
    Zhu, Jun
    Samoilova, Olga
    Suh, Cheolwon
    Matsumura, Itaru
    Lopez-Hernandez, Andres
    Duehrsen, Ulrich
    Thieblemont, Catherine
    Carey, Jodi
    Liu, Grace
    Shreeve, S. Martin
    Sun, Steven
    Vermeulen, Jessica
    Staudt, Louis M.
    Wilson, Wyndham H.
    BLOOD, 2018, 132
  • [43] ACCEPT: A phase Ib/II combination of acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for patients with diffuse large B-cell lymphoma (DLBCL)
    Johnson, Peter W. M.
    Caddy, Joshua
    Cumin, Tom
    Merton, Bridgen
    Maishman, Tom
    Galanopoulou, Angelic
    Griffiths, Gareth
    Davies, Andrew
    CANCER RESEARCH, 2018, 78 (13)
  • [44] A Multicenter Phase II Study Of Bendamustine In Combination With Rituximab In Older Patients With Previously Untreated Diffuse Large B-Cell Lymphoma
    Park, Steven I.
    Richards, Kristy L.
    Asch, Adam S.
    Olajide, Oludamilola
    Deal, Allison M.
    Ivanova, Anastasia
    Wall, James G.
    Sobol, Anna L.
    Foster, Matthew C.
    Muss, Hyman B.
    Shea, Thomas C.
    BLOOD, 2013, 122 (21)
  • [45] A Phase II Study Evaluating Safety and Efficacy of Polatuzumab Vedotin in Combination with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients with Previously Untreated Double and Triple Hit Lymphoma
    Modi, Dipenkumar
    Kim, Seongho
    Pregja, Silva
    Houde, Christiane
    Reichel, Kathy A.
    Ramchandren, Rod
    BLOOD, 2021, 138
  • [46] Magrolimab in Combination with Rituximab plus Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Maakaron, Joseph
    Asch, Adam S.
    Popplewell, Leslie L.
    Collins, Graham P.
    Flinn, Ian W.
    Ghosh, Nilanjan
    Keane, Colin
    Ku, Matthew
    Mehta, Amitkumar
    Roschewski, Mark
    O'Hear, Carol
    Ren, Xuehan
    Villa, Bertha
    Lal, Indu
    Smith, Sonali M.
    Advani, Ranjana H.
    BLOOD, 2022, 140 : 3728 - 3730
  • [47] Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
    Johnson, Nathalie A.
    Slack, Graham W.
    Savage, Kerry J.
    Connors, Joseph M.
    Ben-Neriah, Susana
    Rogic, Sanja
    Scott, David W.
    Tan, King L.
    Steidl, Christian
    Sehn, Laurie H.
    Chan, Wing C.
    Iqbal, Javeed
    Meyer, Paul N.
    Lenz, Georg
    Wright, George
    Rimsza, Lisa M.
    Valentino, Carlo
    Brunhoeber, Patrick
    Grogan, Thomas M.
    Braziel, Rita M.
    Cook, James R.
    Tubbs, Raymond R.
    Weisenburger, Dennis D.
    Campo, Elias
    Rosenwald, Andreas
    Ott, German
    Delabie, Jan
    Holcroft, Christina
    Jaffe, Elaine S.
    Staudt, Louis M.
    Gascoyne, Randy D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (28) : 3452 - 3459
  • [48] Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma
    Ruan, Jia
    Martin, Peter
    Furman, Richard R.
    Lee, Shing M.
    Cheung, Ken
    Vose, Julie M.
    LaCasce, Ann
    Morrison, Julia
    Elstrom, Rebecca
    Ely, Scott
    Chadburn, Amy
    Cesarman, Ethel
    Coleman, Morton
    Leonard, John P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (06) : 690 - 697
  • [49] Is first-line treatment with polatuzumab vedotin-rituximab-cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) for previously untreated diffuse large B-cell lymphoma cost-effective in China? A cost-effectiveness analysis using a Markov model
    Dong, Liangliang
    Zhong, Wanfu
    Chen, Ting
    Zhao, Qiuling
    Liu, Wenbin
    Qiu, Xiuliang
    Huang, Ruyi
    Huang, Shengqiang
    Xie, Ruixiang
    Yang, Lin
    BMJ OPEN, 2025, 15 (01):
  • [50] Zilovertamab Vedotin (ZV) Alone or in Combination With Nemtabrutinib in Relapsed or Refractory (R/R) Aggressive and Indolent B-Cell Malignancies (waveLINE-006): An Open-Label, Phase 2 Basket Study
    Paskiewicz-Kozik, Ewa
    Glimelius, Ingrid
    Moreira, Claudia
    Garrido, Marcelo
    Ernst, Daniel
    Jurczak, Wojciech
    Merryman, Reid
    Kim, Won Seog
    Ozcan, Muhit
    Santoro, Armando
    Sawalha, Yazeed
    Berkovits, Alejandro
    Ren, Yixin
    Ogbu, Uzor
    Yusuf, Rushdia
    Zinzani, Pier Luigi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S483 - S484
12345